Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases

Talawar Therapeutics has entered into a definitive business combination agreement with JATT II Acquisition Corp, a special purpose acquisition company (SPAC), in a transaction valued at approximately $285 million. This agreement was announced on June 29, 2026, and is expected to close in the second half of 2026, pending customary closing conditions, including shareholder approval and regulatory clearances. Upon completion of the transaction, the combined entity will operate under the name Talawar Therapeutics and is anticipated to list on the Nasdaq under the ticker symbol "TLWR."

Talawar Therapeutics is focused on developing bispecific antibodies for inflammatory and immunology diseases, with its lead product candidate, TALA-125, targeting atopic dermatitis. The company was formed to commercialize assets discovered by Khanda Therapeutics, L.P., and aims to address significant unmet needs in the treatment of inflammatory diseases. TALA-125 is designed to combine two clinically validated mechanisms—anti-IL-13 and anti-IL-18—into a single therapy, which is expected to enhance efficacy compared to existing monotherapies. The clinical entry for TALA-125 is projected for the first quarter of 2027, with interim Phase 1 data anticipated in the fourth quarter of 2027.

The business combination will be supported by a concurrent private investment in public equity (PIPE) of $225 million, which has been oversubscribed. This financing is led by Access Biotechnology and includes participation from several notable investors such as Bain Capital Life Sciences and RA Capital Management. The proceeds from the PIPE and the cash held in JATT II's trust account are expected to provide sufficient capital to fund TALA-125 through its Phase 2b proof-of-concept study, with data readout expected in the second half of 2028. This financial backing is crucial for Talawar as it seeks to advance its innovative therapies in a competitive biotechnology landscape.

The biotechnology sector, particularly in the field of immunology and inflammatory diseases, has seen significant activity and investment in recent years. Atopic dermatitis represents a large therapeutic market, yet many patients continue to experience inadequate responses to current treatments. The strategic rationale behind the merger is to leverage the combined resources and expertise of both companies to accelerate the development of TALA-125 and potentially redefine treatment paradigms in this area. Talawar's leadership team, which includes industry veterans with extensive experience in drug development and commercialization, is well-positioned to navigate the complexities of bringing new therapies to market.

In summary, the merger between Talawar Therapeutics and JATT II Acquisition Corp underscores the growing interest in innovative biotechnology solutions for inflammatory and immunology diseases. As the combined company prepares for its public debut, the successful execution of its clinical development plans for TALA-125 could not only enhance patient outcomes but also contribute to the broader evolution of treatment strategies in the field. The anticipated closing of this transaction may signal increased investor confidence in the potential of bispecific antibodies and the ongoing evolution of therapeutic approaches for complex diseases.